{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:21:30Z","timestamp":1791206490276,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10557-018-6790-1","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T05:17:40Z","timestamp":1524201460000},"page":"233-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease"],"prefix":"10.1007","volume":"32","author":[{"given":"Soo-Sang","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"6790_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev.nu.12.070192.001431","volume":"12","author":"S-S Kang","year":"1992","unstructured":"Kang S-S, Wong PWK, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Ann Rev Nutr. 1992;12:279\u201398.","journal-title":"Ann Rev Nutr"},{"key":"6790_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0967-2109(97)00062-8","volume":"5","author":"MR Nehler","year":"1997","unstructured":"Nehler MR, Taylor LM Jr, Porter JM. Homocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Surg. 1997;5:559\u201367.","journal-title":"Cardiovasc Surg"},{"key":"6790_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev.med.49.1.31","volume":"49","author":"H Refsum","year":"1998","unstructured":"Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med. 1998;49:31\u201362.","journal-title":"Ann Rev Med."},{"key":"6790_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-131-5-199909070-00008","volume":"131","author":"JW Eikelboom","year":"1999","unstructured":"Eikelboom JW, Lonn E, Genest J, Henkey Yusuf S. Homocysteine and cardiovascular disease: a critical review of epidemiologic evidence. Ann Intern Med. 1999;131:365\u201375.","journal-title":"Ann Intern Med"},{"key":"6790_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.med.60.041807.123308","volume":"60","author":"BA Maron","year":"2009","unstructured":"Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Ann Rev Med. 2009;60:39\u201354.","journal-title":"Ann Rev Med"},{"key":"6790_CR6","unstructured":"Rosenson RS, Kang DS. Overview of homocysteine. UpToDate. 2017."},{"key":"6790_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1203\/00006450-197910000-00012","volume":"13","author":"S-S Kang","year":"1979","unstructured":"Kang S-S, Wong PWK, Becker N. Protein-bound homocysteine in normal subjects and in patients with homocystinuria. Pediatr Res. 1979;13:1141\u20133.","journal-title":"Pediatr Res"},{"key":"6790_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1203\/00006450-197606000-00008","volume":"10","author":"YS Kanwar","year":"1976","unstructured":"Kanwar YS, Manoligod JR, Wong PWK. Morphological studies in a patient with methylenetetrahydrofolate reductase deficiency. Pediatr Res. 1976;10:598\u2013609.","journal-title":"Pediatr Res"},{"key":"6790_CR9","first-page":"483","volume":"34","author":"ER Baumgartner","year":"1979","unstructured":"Baumgartner ER, Wick H, Linnell JC, Gaul GE. Congenital defect in intracellular cobalamin metabolism resulting in homocysteine and methylmalonicaciduria. Helo Pediatr Acta. 1979;34:483\u201396.","journal-title":"Helo Pediatr Acta"},{"key":"6790_CR10","first-page":"157","volume":"11","author":"KS McCully","year":"1983","unstructured":"McCully KS. Homocysteine theory of arteriosclerosis: development and current status. Atheiosclerosis Rev. 1983;11:157\u2013246.","journal-title":"Atheiosclerosis Rev"},{"key":"6790_CR11","unstructured":"Mudd SH, Levy HL, Skovy F. Disorder of transsulfuration. In: Scriver CR, Beadel AL, Sly WS, Valle D (eds): The metabolic basis of inherited disease, 16th ed. McGraw-Hill 1989. P698."},{"key":"6790_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/0026-0495(88)90076-5","volume":"37","author":"S-S Kang","year":"1987","unstructured":"Kang S-S, Wong PWK, Norusis M, Zhou J, Sora J, Lessck M, et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary heart disease. Metabolism. 1987;37:611\u20133.","journal-title":"Metabolism"},{"key":"6790_CR13","first-page":"536","volume":"48","author":"S-S Kang","year":"1991","unstructured":"Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48:536\u201345.","journal-title":"Am J Hum Genet"},{"key":"6790_CR14","first-page":"1268","volume":"59","author":"P Goyette","year":"1996","unstructured":"Goyette P, Christensen B, Rosenblatt DS, Rozen R. Severe and Mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene and description of five novel mutations in MTHFR. Am J Hum Genet. 1996;59:1268\u201375.","journal-title":"Am J Hum Genet"},{"key":"6790_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1042\/cs0650335","volume":"65","author":"S-S Kang","year":"1983","unstructured":"Kang S-S, Wong PWK, Bidani A, Milanez S. Plasma protein-bound homocysteine in patients regulating chronic hemodialysis. Clin Sci. 1983;65:335\u20136.","journal-title":"Clin Sci"},{"key":"6790_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/00365519109091615","volume":"51","author":"B Haltberg","year":"1991","unstructured":"Haltberg B, Agaidh E, Anderson A, et al. Increased levels of homocysteine are associated with nephropathy. Clin Lab Investig. 1991;51:277\u201382.","journal-title":"Clin Lab Investig"},{"key":"6790_CR17","unstructured":"Kang S-S, Wong PWK, Barnes LJ. Severe homocysteinemia in a non-homocystinuric subject. Unpublished Communication, 1984."},{"key":"6790_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/0026-0495(87)90043-6","volume":"36","author":"S-S Kang","year":"1987","unstructured":"Kang S-S, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 1987;36:458\u201362.","journal-title":"Metabolism"},{"key":"6790_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0165-6147(90)90148-2","volume":"11","author":"H Refsum","year":"1990","unstructured":"Refsum H, Ueland PM. Clinical significance of pharmacological modulation of homocysteine metabolism. Trans Pharmacol Sci. 1990;11:411\u20136.","journal-title":"Trans Pharmacol Sci"},{"key":"6790_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0026-0495(88)90093-5","volume":"37","author":"DEL Wilcken","year":"1988","unstructured":"Wilcken DEL, Dudman NPB, Tyrrell DA. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency. Metabolism. 1988;37:697\u2013701.","journal-title":"Metabolism"},{"key":"6790_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ajcn\/77.1.63","volume":"77","author":"R Meleady","year":"2003","unstructured":"Meleady R, Ueland PM, Blom H, Whitehead AS, Refsum H, Daly LE, et al. And the EC concerted action project: homocysteine and vascular disease. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am J Clin Nutr. 2003;77:63\u201370.","journal-title":"Am J Clin Nutr"},{"key":"6790_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11883-007-0048-x","volume":"9","author":"BA Maron","year":"2007","unstructured":"Maron BA, Loscalzo J. Should hyperhomocysteinemia be treated in patients with atherosclerotic disease? Curr Atheroscler Rep. 2007;9:375\u201383.","journal-title":"Curr Atheroscler Rep"},{"key":"6790_CR23","first-page":"546","volume":"48","author":"S-S Kang","year":"1991","unstructured":"Kang S-S, Wong PWK, Bock HG, et al. Intermediate hyperhomocyteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutation. Am J Hum Gene. 1991;48:546\u201351.","journal-title":"Am J Hum Gene"},{"key":"6790_CR24","doi-asserted-by":"publisher","first-page":"1273S","DOI":"10.1093\/jn\/126.suppl_4.1273S","volume":"126","author":"S-S Kang","year":"1996","unstructured":"Kang S-S. Treatment of hyperhomocysteinemia: physiological basis. J Nut. 1996;126:1273S\u20135S.","journal-title":"J Nut"},{"key":"6790_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1191\/1358863x02vm428ra","volume":"7","author":"N Weiss","year":"2003","unstructured":"Weiss N, Keller C, Hoffman U, et al. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med. 2003;7:227\u201339.","journal-title":"Vasc Med"},{"key":"6790_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF00445602","volume":"142","author":"U Wendell","year":"1984","unstructured":"Wendell U, Bremer HJ. Betaine in the treatment of homocystinuria due to 5,19-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 1984;142:147\u201350.","journal-title":"Eur J Pediatr"},{"key":"6790_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/adc.64.7.1061","volume":"60","author":"E Holm","year":"1989","unstructured":"Holm E, Kjellman B, Ronge E. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Childh. 1989;60:1061\u20134.","journal-title":"Arch Dis Childh"},{"key":"6790_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ndt\/13.1.106","volume":"13","author":"C Guldner Van","year":"1998","unstructured":"Van Guldner C, Janssen MJFM, Lambert J, et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in hemodialysis patients. Nephr Dialy Transp. 1998;13:106\u201312.","journal-title":"Nephr Dialy Transp"},{"key":"6790_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/ndt\/gfl044","volume":"21","author":"C Guldner Van","year":"2006","unstructured":"Van Guldner C. Why is homocysteinemia elevated in renal failure and what can be expected from homocysteine lowering. Nephr Dialys Transp. 2006;21:1161\u20136.","journal-title":"Nephr Dialys Transp"},{"key":"6790_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/01.STR.25.5.943","volume":"25","author":"P Rubba","year":"1994","unstructured":"Rubba P, Mercuri M, Faccenda F, Iannuzzi A, Irace C, Strisciuglio P, et al. Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and homocystinuria? Stroke. 1994;25:943\u201350.","journal-title":"Stroke"},{"key":"6790_CR31","first-page":"40","volume":"7","author":"RB Singh","year":"2002","unstructured":"Singh RB, Meng SA, Xu Y-J, et al. Pathogenesis of arteriosclerosis: a multifactorial process. Exp Clin Cardiol. 2002;7:40\u201353.","journal-title":"Exp Clin Cardiol"},{"key":"6790_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrm.2017.36","volume":"18","author":"M Potente","year":"2017","unstructured":"Potente M, Makinen T. Vascular heterogeneity and specialization in development and disease. Nat Rev Mol Cell Biol. 2017;18:477\u201394.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6790_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0163-7258(98)00005-9","volume":"78","author":"E Thorin","year":"1988","unstructured":"Thorin E, Shreeve SM. Heterogeneity of vascular endothelial cells in normal and disease states. Pharmacol Ther. 1988;78:155\u201366.","journal-title":"Pharmacol Ther"},{"key":"6790_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0021-9150(87)90018-9","volume":"65","author":"DL Sprecher","year":"1987","unstructured":"Sprecher DL, Kruth HS, Piece JE, et al. A familial basis for the heterogeneity atherosclerotic disease. Atherosclerosis. 1987;65:167\u201372.","journal-title":"Atherosclerosis"},{"key":"6790_CR35","doi-asserted-by":"crossref","unstructured":"Box LC, Angiolillo DJ, Suzuki N, Box LA, Jiang J, Guzman L, et al. Heterogeneity of atherosclerotic plaque characteristics in human coronary artery disease: a three dimensional intravascular ultrasound study. Catheter Cardiovasc Interv. 2007;70:349\u201356.","DOI":"10.1002\/ccd.21088"},{"key":"6790_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jama.291.5.565","volume":"291","author":"JF Toole","year":"2004","unstructured":"Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291:565\u201375.","journal-title":"JAMA"},{"key":"6790_CR37","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa060900","volume":"354","author":"E Lonne","year":"2006","unstructured":"Lonne E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567\u201377.","journal-title":"N Engl J Med"},{"key":"6790_CR38","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJMoa055227","volume":"354","author":"KH Bonna","year":"2006","unstructured":"Bonna KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578\u201388.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6790-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T23:09:52Z","timestamp":1555715392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6790-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["6790"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6790-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"20 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}